- March 15, 2022
- Newsletter
- 617-430-5616
Menu
Menu
Menu
Menu
Menu
Menu
Brand Name :
Altace
(United States) [Available] ,AG-ramipril
(United States) [Pending for FDA approval]Synonyms :
ACT-Ramipril,Auro-remipril,RAN-Ramipril
Class :
Angiotensin-converting enzyme inhibitors, Antihypertensive
Dosage Forms & Strengths
Capsule
1.25mg
2.5mg
5mg
10mg
2.5
mg
Orally
once a day
without taking a diuretic; and increase up to 2.5-20 mg/day in divided doses
congestive Heart Failure (CHF)
2.5
mg
Orally
twice a day
; increase up to 5 mg
congestive Heart Failure (CHF)
2.5
mg
Orally
twice a day
; increase up to 5 mg
Off-label:
2.5
mg
Orally
daily without taking a diuretic; 1.25 mg orally with diuretics
2.5
mg
Orally
daily 1 week, following 5 mg Daily for 3 weeks
may increase the adverse effect of angiotensin ii receptor blockers
may increase the adverse effect of angiotensin ii receptor blockers
may increase the adverse effect of angiotensin ii receptor blockers
may increase the adverse effect of angiotensin ii receptor blockers
may increase the adverse effect of angiotensin ii receptor blockers
may have an increased hyperkalemic effect when combined with angiotensin-converting enzyme inhibitors
may have an increasingly adverse effect when combined with angiotensin-converting enzyme inhibitors
may have an increasingly adverse effect when combined with angiotensin-converting enzyme inhibitors
may have an increasingly adverse effect when combined with angiotensin-converting enzyme inhibitors
may have an increasingly adverse effect when combined with angiotensin-converting enzyme inhibitors
may have an increasingly adverse effect when combined with angiotensin-converting enzyme inhibitors
may have an increasingly adverse effect when combined with ACE inhibitors
may enhance the concentration of serum when combined with lithium
may increase the adverse effect of telmisartan
it may either increases toxicity of the other by pharmacodynamic synergism
may diminish the effects of ketoprofen by pharmacodynamic antagonism
may diminish the effects of indomethacin by pharmacodynamic antagonism
grass pollens allergen extract
may have an increasingly adverse effect when combined with grass pollen extract
may have an increased risk of renal failure, hypertension, and hyperkalemia when combined with ramipril
Enhance the neuromuscular effect of NMBAs
Enhance the neuromuscular effect of NMBAs
Enhance the neuromuscular effect of NMBAs
Enhance the neuromuscular effect of NMBAs
Enhance the neuromuscular effect of NMBAs
choline magnesium trisalicylate
may enhance the nephrotoxic effect of ACE inhibitors
may enhance the adverse/toxic effect of NSAIDs
may enhance the adverse/toxic effect of NSAIDs
may enhance the adverse/toxic effect of NSAIDs
may enhance the adverse/toxic effect of NSAIDs
may enhance the adverse/toxic effect of NSAIDs
may increase the risk of adverse/toxic effects
may increase the risk of adverse/toxic effects
may increase the risk of adverse/toxic effects
may increase the risk of adverse/toxic effects
may increase the risk of adverse/toxic effects
may increase the toxic effects
may increase the toxic effects
may increase the toxic effects
may increase the toxic effects
may increase the toxic effects
may have an increased therapeutic effect when combined with angiotensin II receptor blocker
may have an increased therapeutic effect when combined with angiotensin II receptor blocker
may have an increased myelosuppressive effect when combined with azathioprine
may have an increased hyperkalemic effect when combined with angiotensin-converting enzyme inhibitors
spironolactone and hydrochlorothiazide
may increase the hyperkalemic effect of ACE Inhibitors
may increase the hyperkalemic effect of ACE Inhibitors
may increase the hyperkalemic effect of ACE Inhibitors
may increase the hyperkalemic effect of ACE Inhibitors
may increase the hyperkalemic effect of ACE Inhibitors
may increase the hyperkalemic effect when combined with ace inhibitors
may increase the toxic effects of dipeptidyl peptidase-IV inhibitors
may have an increasingly adverse effect when combined with angiotensin-converting enzyme inhibitors
may have an increasingly adverse effect when combined with angiotensin-converting enzyme inhibitors
Adverse drug reactions:
Frequency Defined
>10%
Cough
1-10%
Nausea
Vomiting
Angina pectoris
Dizziness
Diarrhea
Syncope
Headache
Vertigo
<1%
Angioedema
Pregnancy warnings:
AU TGA pregnancy category: D
US FDA pregnancy category: D
Lactation:
Excreted into human milk is unknown
Pregnancy Categories:
Category A: Satisfactory and well-controlled studies show no risk to the fetus in the first or later trimester.
Category B: No evidence shown of risk to the fetus found in animal reproduction studies, and there are not enough studies on pregnant women
Category C: Adverse effects on the fetus found with evidence in animal reproduction studies and no adequate evidence for a result in humans must take care of potential risks in pregnant women
Category D: adequate data available with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.
Category N: There is no data available for the drug under this category
Patient Information Leaflet
Generic Name: ramipril
Why do we use ramipril?
ramipril is an Angiotensin Converting Enzyme (ACE) Inhibitors. It is used to treat Hypertension, MI, congestive heart failure, and Diabetic Nephropathy.
ADVERTISEMENT
